Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 10, No 4 (2017) INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW Abstract  similar documents
D. G. Tolkacheva, A. V. Torgov, A. S. Margazova
"... the reference group of drugs. However, today’s control of biosimilar pricing in Europe is just building up ..."
 
Vol 10, No 4 (2017) INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW Abstract  similar documents
D. G. Tolkacheva, A. V. Torgov, A. S. Margazova
"... the reference group of drugs. However, today’s control of biosimilar pricing in Europe is just building up ..."
 
Vol 11, No 1 (2018) Options to optimize the access to biosimilars: analysis and solutions Abstract  similar documents
O. V. Kirsanova, V. V. Omelyanovsky
"... products – biosimilars – in the Russian Federation and elsewhere (USA, EU) are  addressed. We propose ..."
 
Vol 11, No 3 (2018) What is the role of antineoplastic drug safety in reimbursement decision making? Abstract  similar documents
A. S. Kolbin, A. A. Kurylev
"... Rationale. From 2014 to 2017, the portion of antineoplastic drugs dossiers submitted ..."
 
Vol 11, No 1 (2018) Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... disappears, and the CA drugs have a lower CER instead. For the «number of  hospitalization-free days per year ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... was increased to 24 months, this economic advantage of AA diminished, and the kA drugs had a lower CeR instead ..."
 
Vol 10, No 4 (2017) THE INTERNATIONAL PRACTICE OF DRUG SUPPLY IN THE OUTPATIENT SEGMENT Abstract  similar documents
D. V. Lukyantseva, L. S. Mel’nikova, A. P. Tatarinov
"... The paper examines the international experience of drug supply and the risks faced by countries ..."
 
Vol 11, No 1 (2018) Modeling microbial drug-resistance: from mathematics to pharmacoeconomics Abstract  similar documents
Yu. M. Gomon, M. A. Arepyeva, Yu. E. Balykina, A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, S. V. Sidorenko
"... optimal algorithm for using antimicrobial agents (AMA) that would minimize the evolving drug-resistance ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
"... are registered in second-line, however only dasatinib is included in the government drug reimbursement program ..."
 
Vol 11, No 3 (2018) The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia Abstract  similar documents
V. V. Omelyanovsky, V. K. Fedyaeva, N. Z. Musina
 
Vol 10, No 4 (2017) IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET Abstract  similar documents
V. A. Lemeshko, N. Z. Musina, V. K. Fedyaeva
"... The current approaches to the drug pricing commonly used worldwide allow for incorporating ..."
 
Vol 11, No 3 (2018) Use of medications in children hospitalized with community-acquired pneumonia Abstract  similar documents
D. D. Siukaeva, I. A. Narkevich, V. N. Timchenko, O. D. Nemyatyh, N. A. Maslova
"... respiratory tract prevailed (32.20%). As for the medications, the category J drugs “Antimicrobials of systemic ..."
 
Vol 11, No 2 (2018) Regional adaptation of the federal model of reimbursement for medical assistance based on clinical statistical groups: hospitalization of patients in need of genetically enginered biological preparations Abstract  similar documents
M. V. Sura, T. N. Ignatova, N. S. Rudneva, Yu. N. Sukhanova, N. G. Ulyanova, A. S. Khudyaev, V. A. Shelyakin, D. V. Scherbakov
"... in the costs of different drug therapy regimens. ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
"... from analysis of published clinical and observational studies. The prices of the relevant drugs were ..."
 
Vol 11, No 3 (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Abstract  similar documents
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
"... . In the ocrelizumab group, the most common adverse events were caused by reactions to the drug infusion ..."
 
1 - 15 of 15 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)